|
1
|
Gompelmann D, Eberhardt R and Herth FJ:
Advanced malignant lung disease: What the specialist can offer.
Respiration. 82:111–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katlic MR, Facktor MA, Berry SA, McKinley
KE, Bothe A Jr and Steele GD Jr: ProvenCare lung cancer: A
multi-institutional improvement collaborative. CA Cancer J Clin.
61:382–396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malapelle U, Pisapia P, Rocco D, Smeraglio
R, di Spirito M, Bellevicine C and Troncone G: Next generation
sequencing techniques in liquid biopsy: Focus on non-small cell
lung cancer patients. Transl Lung Cancer Res. 5:505–510. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Langer F, Helsberg K, Schütte WH and
Leschinger MI: Gemcitabine in the first line therapy of advanced
and metastatic non-small-cell lung carcinoma (NSCLC): Review of the
results of phase III studies. Onkologie. 28 Suppl 1:S1–S28.
2005.(In German).
|
|
7
|
Laskin JJ and Sandler AB: First-line
treatment for advanced non-small-cell lung cancer. Oncology
(Williston Park). 19:1671–1680. 2005.PubMed/NCBI
|
|
8
|
Gallelli L, Nardi M, Prantera T, Barbera
S, Raffaele M, Arminio D, Pirritano D, Colosimo M, Maselli R,
Pelaia G, et al: Retrospective analysis of adverse drug reactions
induced by gemcitabine treatment in patients with non-small cell
lung cancer. Pharmacol Res. 49:259–263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang B and Cui J: Treatment of mid-late
stage NSCLC using sodium cantharidinate/vitamin B6/GP regimen in
clinic. J Cancer Res Ther. 10 Suppl 1:C79–C81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu B and Tao ZZ: Piceatannol enhances the
antitumor efficacy of gemcitabine in human A549 non-small cell lung
cancer cells. Oncol Res. 22:213–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karampeazis A, Vamvakas L, Kentepozidis N,
Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A,
Hatzidaki D, Pallis AG and Georgoulias V: Biweekly carboplatin plus
gemcitabine as first-line treatment of elderly patients with
advanced squamous non-small-cell lung cancer: A multicenter phase
I–II trial by the hellenic oncology research group. Clin Lung
Cancer. 17:543–549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshitomi S, Taira N, Doihara H, Mizoo T,
Nogami T, Iwamoto T, Motoki T, Shien T, Ogasawara Y, Matsuoka J, et
al: A phase 1, dose-finding and pharmacokinetic study of
gemcitabine with nab-paclitaxel in patients with metastatic breast
cancer. Cancer Chemother Pharmacol. 78:289–294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sha O, Niu J, Ng TB, Cho EY, Fu X and
Jiang W: Anti-tumor action of trichosanthin, a type 1
ribosome-inactivating protein, employed in traditional Chinese
medicine: A mini review. Cancer Chemother Pharmacol. 71:1387–1393.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Au TK, Collins RA, Lam TL, Ng TB, Fong WP
and Wan DC: The plant ribosome inactivating proteins luffin and
saporin are potent inhibitors of HIV-1 integrase. FEBS Lett.
471:169–172. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Byers VS, Levin AS, Malvino A, Waites L,
Robins RA and Baldwin RW: A phase II study of effect of addition of
trichosanthin to zidovudine in patients with HIV disease and
failing antiretroviral agents. AIDS Res Hum Retroviruses.
10:413–420. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sha O, Yew DT, Ng TB, Yuan L and Kwong WH:
Different in vitro toxicities of structurally similar type I
ribosome-inactivating proteins (RIPs). Toxicol In Vitro.
24:1176–1182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ng TB, Wong JH and Wang H: Recent progress
in research on ribosome inactivating proteins. Curr Protein Pept
Sci. 11:37–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu Y, Sun Y, Cai Y, Sha O and Jiang W:
Trichosanthin reduces the viability of SU-DHL-2 cells via the
activation of the extrinsic and intrinsic apoptotic pathways. Mol
Med Rep. 13:403–411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ouyang DY, Chan H, Wang YY, Huang H, Tam
SC and Zheng YT: An inhibitor of c-Jun N-terminal kinases
(CEP-11004) counteracts the anti-HIV-1 action of trichosanthin.
Biochem Biophys Res Commun. 339:25–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang H, Chan H, Wang YY, Ouyang DY, Zheng
YT and Tam SC: Trichosanthin suppresses the elevation of p38 MAPK
and Bcl-2 induced by HSV-1 infection in Vero cells. Life Sci.
79:1287–1292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang P, Yan H and Li JC: CREB-mediated
Bcl-2 expression in trichosanthin-induced Hela cell apoptosis.
Biochem Biophys Res Commun. 363:101–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li M, Chen F, Liu CP, Li DM, Li X, Wang C
and Li JC: Dexamethasone enhances trichosanthin-induced apoptosis
in the HepG2 hepatoma cell line. Life Sci. 86:10–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang D, Chen B, Zhou J, Zhou L, Li Q, Liu
F, Chou KY, Tao L and Lu LM: Low concentrations of trichosanthin
induce apoptosis and cell cycle arrest via c-Jun N-terminal protein
kinase/mitogen-activated protein kinase activation. Mol Med Rep.
11:349–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li CT, Lin CH, Kao TY, Wu MF, Yeh CS, Yeh
KT and Ko JL: The mechanisms of action of Tianhua(™) on antitumor
activity in lung cancer cells. Pharm Biol. 48:1302–1309. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhaskar PT and Hay N: The two TORCs and
Akt. Dev Cell. 12:487–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J: Is Src the key to understanding
metastasis and developing new treatments for colon cancer? Nat Clin
Pract Gastroenterol Hepatol. 5:306–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR,
Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis
factor requires the Akt serine-threonine kinase. Nature. 401:82–85.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao C, Gao W and Chen T: Synergistic
induction of apoptosis in A549 cells by dihydroartemisinin and
gemcitabine. Apoptosis. 19:668–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Pan YY and Zhang Y: Synergistic
interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive
and EGFR-TKI-resistant human lung cancer cell lines. Oncol Lett.
5:440–446. 2013.PubMed/NCBI
|
|
31
|
Li T: Pacilitaxel induces human
nasopharyngeal carcinoma cell line CNE2 apoptosis and growth
inhibition by suppressing PI3K/AKT/p53 signaling pathway. Lin Chung
Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 29:2147–2150. 2015.(In
Chinese). PubMed/NCBI
|
|
32
|
Lu D, Qian J, Li W, Feng Q, Pan S and
Zhang S: β-hydroxyisovaleryl-shikonin induces human cervical cancer
cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett.
10:3434–3442. 2015.PubMed/NCBI
|
|
33
|
Zhao J, Zhang ZR, Zhao N, Ma BA and Fan
QY: VEGF silencing inhibits human osteosarcoma angiogenesis and
promotes cell apoptosis via PI3K/AKT signaling pathway. Cell
Biochem Biophys. 73:519–525. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin H, Qiao F, Wang Y, Xu Y and Shang Y:
Curcumin inhibits cell proliferation and induces apoptosis of human
non-small cell lung cancer cells through the upregulation of
miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol
Rep. 34:2782–2789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mu GG, Zhang LL, Li HY, Liao Y and Yu HG:
Thymoquinone pretreatment overcomes the insensitivity and
potentiates the antitumor effect of gemcitabine through abrogation
of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic
cancer. Dig Dis Sci. 60:1067–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yoon SH, Ramalingam M and Kim SJ: Insulin
stimulates integrin-linked kinase in UMR-106 cells: Potential role
of heparan sulfate on syndecan-1. J Recept Signal Transduct Res.
35:613–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ha Ju H and Kim SJ: Association of insulin
receptor and syndecan-1 by insulin with activation of ERK I/II in
osteoblast-like UMR-106 cells. J Recept Signal Transduct Res.
33:37–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang QY, Wang L, Song ZY and Qu XJ:
Knockdown of type I insulin-like growth factor receptor inhibits
human colorectal cancer cell growth and downstream PI3K/Akt,
WNT/β-catenin signal pathways. Biomed Pharmacother. 73:12–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Q, Li X, Li C, Zheng Y and Peng G:
1-Deoxynojirimycin alleviates insulin resistance via activation of
insulin signaling PI3K/AKT pathway in skeletal muscle of db/db
mice. Molecules. 20:21700–21714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma Y, Zhang P, Gao Y, Fan H, Zhang M and
Wu J: Evaluation of AKT phosphorylation and PTEN loss and their
correlation with the resistance of rituximab in DLBCL. Int J Clin
Exp Pathol. 8:14875–14884. 2015.PubMed/NCBI
|
|
41
|
Deng QF, Su BO, Zhao YM, Tang L, Zhang J
and Zhou CC: Integrin β1-mediated acquired gefitinib resistance in
non-small cell lung cancer cells occurs via the phosphoinositide
3-kinase-dependent pathway. Oncol Lett. 11:535–542. 2016.PubMed/NCBI
|
|
42
|
Awasthi N, Zhang C, Ruan W, Schwarz MA and
Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like
growth factor-1 receptor/insulin receptor, enhances gemcitabine
response in pancreatic cancer. Mol Cancer Ther. 11:2644–2653. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Okusaka T, Ikeda M, Fukutomi A, Kobayashi
Y, Shibayama K, Takubo T and Gansert J: Safety, tolerability,
pharmacokinetics and antitumor activity of ganitumab, an
investigational fully human monoclonal antibody to insulin-like
growth factor type 1 receptor, combined with gemcitabine as
first-line therapy in patients with metastatic pancreatic cancer: A
phase 1b study. Jpn J Clin Oncol. 44:442–447. 2014. View Article : Google Scholar : PubMed/NCBI
|
